Early drug trial for eczema halted after limited testing
NCT ID NCT06119529
Summary
This early-stage study aimed to test the safety of a new drug called LY3872386. It involved healthy volunteers and people with atopic dermatitis (eczema) to see how their bodies handled the drug. The study was terminated early, so no final results on effectiveness are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel ACT
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.